WASHINGTON — Sen. Elizabeth Warren, D-Mass., urged the Defense Department to audit Express Scripts to determine if the pharmacy benefit manager is overcharging for prescriptions and steering military ...

A federal appeals court granted Express Scripts Inc. ‘s petition for a jury trial in a case from 120 cities, towns, and counties across West Virginia alleging the company played a central role in the ...

Express Scripts agreed to pay a $1.5 million administrative penalty and implement corrective actions following an investigation by the West Virginia Offices of the Insurance Commissioner. Between May ...

On February 4, 2026, Express Scripts agreed to a settlement with the Federal Trade Commission (FTC) in the agency’s administrative case against the nation’s three largest pharmacy benefit managers ...

The Federal Trade Commission has announced what it called a "landmark settlement" with Express Scripts over insulin pricing. The settlement resolves a lawsuit alleging that Express Scripts' conduct ...

The FTC first sued Express Scripts, CVS Caremark, and Optum in 2024, claiming anticompetitive and unfair rebating practices surrounding insulin. “Caremark, [Express Scripts], and Optum—as medication ...

FTC allegations centered on “Big 3” PBMs using anticompetitive rebating and affiliated-pharmacy channel dynamics to inflate insulin list prices and capture rebate and margin-driven revenues.

The Federal Trade Commission said it has reached a settlement with Express Scripts, resolving an earlier lawsuit that alleged the pharmacy benefit manager artificially inflated insulin drug prices.

The Federal Trade Commission has agreed to what it called a “landmark” settlement with Express Scripts, allowing the company to bow out of the agency’s lawsuit against major pharmacy benefit managers ...

The Trump administration announced that the company, a pharmacy benefit manager, had agreed to make significant changes to its practices. By Rebecca Robbins and Reed Abelson The reporters have ...

Ed’s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation, and legislation. He is also the author of the morning Pharmalittle newsletter ...